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Background: The breast and ovarian cancer susceptibility gene (BRCA1) encodes a tumor suppressor. The BRCA1
protein is found primarily in cell nuclei and plays an important role in the DNA damage response and
transcriptional regulation. Deficiencies in DNA repair capabilities have been associated with higher histopathological
grade and worse prognosis in breast cancer.
Methods: In order to investigate the subcellular distribution of BRCA1 in tumor tissue we randomly selected 22
breast carcinomas and tested BRCA1 protein localization in frozen and contiguous formalin-fixed, paraffin
embedded (FFPE) tissue, using pressure cooker antigen-retrieval and the MS110 antibody staining. To assess the
impact of BRCA1 germline mutations on protein localization, we retrospectively tested 16 of the tumor specimens
to determine whether they contained the common Ashkenazi Jewish founder mutations in BRCA1 (185delAG,
5382insC), and BRCA2 (6174delT). We also compared co-localization of BRCA1 and nucleolin in MCF7 cells (wild
type) and a mutant BRCA1 cell line, HCC1937 (5382insC).
Results: In FFPE tissue, with MS110 antibody staining, we frequently found reduced BRCA1 nuclear staining in
breast tumor tissue compared to normal tissue, and less BRCA1 staining with higher histological grade in the
tumors. However, in the frozen sections, BRCA1 antibody staining showed punctate, intra-nuclear granules in
varying numbers of tumor, lactating, and normal cells. Two mutation carriers were identified and were confirmed
by gene sequencing. We have also compared co-localization of BRCA1 and nucleolin in MCF7 cells (wild type) and
a mutant BRCA1 cell line, HCC1937 (5382insC) and found altered sub-nuclear and nucleolar localization patterns
consistent with a functional impact of the mutation on protein localization.
Conclusions: The data presented here support a role for BRCA1 in the pathogenesis of sporadic and inherited
breast cancers. The use of well-characterized reagents may lead to further insights into the function of BRCA1 and
possibly the further development of targeted therapeutics.
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Germline mutations in the breast cancer tumor suppres-
sor genes BRCA1 [1-3] and BRCA2 [4,5] have been found
in familial breast and ovarian cancer. Prevalence of muta-
tions in patients aged 20 to 74 years with breast cancer
were reported to be 3.3%; a finding which did not provide
support for screening of the general population [6]. Breast* Correspondence: natalietulchin2@gmail.com
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reproduction in any medium, provided the orcancer patients aged 35 years or younger and individuals
less than age 45 with first-degree family history of breast
cancer had mutation prevalence of about 6.5 and 7%, re-
spectively [7]. Lidereau et al. [8] found they could improve
the likelihood of detecting BRCA1 mutations in a series of
patients with invasive breast cancer, under 35 years of age,
when they selected patients with estrogen receptor (ER)
negative, high grade tumors (37%). Approximately 2% of
Ashkenazi Jews carry mutations in BRCA1 or BRCA2 that
confer, at age 70, an estimated risk of breast cancer of 56%
[9,10]. However, somatic BRCA1 mutations have not beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Tumor genotype and BRCA1 staining




1. PDA +++ N.A. −/+ N.T.M.
2. MDA ++ +++ +/+ N.T.M.
3. PDA +++ ++ +/+ N.T.M.
4. PDA +++ ++++ −/− BRCA2
6174delT
5. PDA ++++ +++ +/+ N.T.M.
6. MDA ++ ++ +/+ N.T.M.
7. MDA,lob ++ ++ +/+ N.T.M.
8. PDA ++ +++ +/− N.A.
9. Medullary ++ N.A. −/− N.A.
10. Mixed,lob& duct. ++++ ++++ +/− N.T.M.
11. PDA ++ + −/− N.T.M.
12. MDA-PDA ++ ++ +/+ N.T.M.
13. PDA ++ + −/− BRCA1
185delAG
14. MDA-PDA +++ +++ +/+ N.T.M.
15. PDA ++ + +/+ N.T.M.
16. Lobular +++ +++ +/+ N.A.
17. PDA ++ ++ +/− N.A.
18. MDA +++ +++ +/+ N.A.
19. MDA ++ ++ +/− N.A.
20. MDA-PDA ++ ++++ +/+ N.T.M.
21. PDA ++ ++ −/− N.T.M.
22. PDA ++ ++ +/+ N.T.M.
ER/PR= Estrogen/Progesterone Receptor.
MDA= Moderately differentiated adenocarcinoma.
PDA= Poorly differentiated adenocarcinoma.
N.A.= not available.
N.T.M.= no targeted mutations.
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though as a tumor suppressor it is thought that BRCA1
participates in tumorigenesis through reduction in BRCA1
mRNA, protein levels, and changes in BRCA1 promoter
methylation [11-17]. Recently, BRCA1 mutations have
been shown to render breast cancer tumors sensitive to
poly (ADP-ribose) polymerase (PARP) inhibition [18].
Sensitivity to PARP inhibitors is thought to be due to a
synthetic lethal combination of the inhibitor-induced
single-strand break repair deficiency along with loss of the
homologous recombination (HR) function of BRCA1 [19].
BRCA1 protein immunohistological staining with the
MS110 antibody has shown a speckled nuclear pattern in
many breast and ovarian cancer cell lines, as well as in
centrosomes and mitochondria [20,21]. Scully et al. [22]
described nuclear staining in breast and ovarian cancer
cell lines with four monoclonal anti-BRCA1 antibodies
and after microwave heating of neutral buffered FFPE sec-
tions of primary invasive ductal carcinomas. However,
Chen et al. [23] described anti-BRCA1 antibodies which
detected cytoplasmic staining in a variety of normal and
cancer cell lines, and mixed cytoplasmic and nuclear stain-
ing in FFPE breast cancer tissues. Wilson et al. [24] tested
19 anti-BRCA1 antibodies which detected a 220 kD pro-
tein localized to nuclear foci in epithelial cell lines from
breast malignancies. In FFPE specimens, more uniform
nuclear staining was observed in benign breast, invasive
lobular cancers, and low grade ductal cancer, while less or
absent staining was found in the majority of high-grade
ductal carcinomas and breast cancer tissue from patients
with BRCA1 185 del AG mutations. However, BRCA1
protein staining remains controversial because of ques-
tions about the specificity of antibodies, variations in stain-
ing protocols, and staining of lymphocytes in surrounding
stromal tissue [25].
Our previous studies have shown that BRCA1 protein
is localized in tumor cell nuclei and nucleoli in frozen
tissue sections, and is co-localized with nucleolin in
MCF7 and HeLa cells [26,27]. Chambon et al. [28] have
shown in light and electron microscopic studies of
estradiol-treated MCF7 cells that BRCA1 nuclear stain-
ing was found in dots around nucleoli, and in the cyto-
plasm in multivesicular bodies near the Golgi.
In the present study, we show similarities and concord-
ance of BRCA1 protein localization between frozen and
pressure cooker antigen-retrieved FFPE tissue in 22 ran-
domly selected breast carcinomas. We further character-
ized our randomly selected population, by retrospectively
genotyping 16 of our anonymized samples for Ashkenazi
Jewish mutations BRCA1 (185delAG, 5382insC) and
BRCA2 (6174delT). We found two specimens with muta-
tions, one from patient no. 4, with a BRCA2 (6174delT)
mutation, and one from patient no. 13, with a BRCA1
(185delAG) mutation, which were subsequently confirmedby DNA sequencing. With immunofluorescence staining
and confocal microscopy, we were able to detect BRCA1
sub-nuclear localization in frozen breast cancer tissue
specimens and co-localization of BRCA1 and nucleolin in
MCF7 (hemizygous for BRCA1 wild type), and HCC1937
(BRCA1 5382insC) cells.
Results
We found variable BRCA1 protein immunostaining in
tumor cell nuclei in frozen tissue sections with the AP16
and K-18 antibodies and with the MS110 antibody in
contiguous FFPE tissues of randomly selected breast car-
cinomas (Table 1, Figures 1, 2, 3, 4, 5, 6 and 7). In frozen
sections, we found variable punctate nuclear staining
(Figures 1, 2, 6, and 7) and we show distinct nuclear
staining, and moderate staining in Figure 4. There was
concordance between frozen and FFPE section staining
in tumor cell nuclei amongst the histological types, with
Figure 1 BRCA1 protein in frozen and FFPE sections of moderately differentiated adenocarcinoma (MDA) from patient no. 2. A. H&E
stained frozen section of the tumor. B. Consecutive section of the same tumor stained with the mouse monoclonal AP16 antibody and the
avidin-biotin peroxidase detection system showed that many of the cells exhibited multifocal dot-like nuclear staining of category (2); insert
shows subnuclear foci. C. Negative control section using standard dilutions of mouse IgG showed essentially no staining. D. H&E section of FFPE
tissue from patient no. 2. E. Consecutive section of the same tumor treated with pressure cooker antigen retrieval and stained with the MS110
antibody showed that most of the cells exhibited moderate nuclear staining of category (3); insert shows dark staining. F. Consecutive control
section of FFPE tissue without primary antibody. (×200) inserts (×2000).
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(Table 1). In FFPE stained tumor tissue, the majority of
the poorly differentiated adenocarcinomas (PDAs) were
in the weak, faint, (1), or distinct (2) staining categories,
and less in the moderate (3), and strong (4) staining
group. The MDA-PDA, and MDA, lobular specimens
showed more elevated levels of staining in both frozen
and FFPE sections (Table 1).Figure 2 BRCA1 protein in frozen and FFPE sections of moderately di
H&E stained frozen section of tumor. B. Consecutive section of the same tu
anti-mouse IgG and avidin-biotin-peroxidase detection system showed tha
category (2); insert shows focal staining . C. Standard dilution of mouse IgG
patient no.7. E. Consecutive section of the same tumor treated with pressu
showed that many of the cells exhibited distinct nuclear staining (2); insert
without primary antibody. (×200) insert (×2000).In some of our samples, we found less positive BRCA1
nuclear staining in FFPE breast tumor tissue compared
to normal tissue as in this example from patient no.19
(Figure 3).We also found strongly stained normal tissue in
specimens nos. 2, 15, 20, and 22; however, we found
weakly stained normal tissue from patients nos. 13, and 17.
In our 16 anonymized frozen tissue samples tested
for BRCA Ashkenazi founder mutations, we detectedfferentiated, lobular carcinoma (MDA-lob) from patient no.7. A.
mor stained with mouse monoclonal AP16 antibody and biotinylated
t many of the cells showed distinct, punctate nuclear staining of
served as a negative control. D. H&E section of FFPE tissue from
re cooker antigen retrieval and stained with the MS110 antibody
shows light staining. F. Consecutive control section of FFPE tissue
Figure 3 BRCA1 protein localization in normal and tumor FFPE sections of poorly differentiated adenocarcinoma (PDA) from patient
no.19. A. H&E section of FFPE normal tissue. B. Consecutive section of the normal tissue stained with the MS110 antibody showed strong
epithelial cell nuclear staining. C. Consecutive control section of FFPE tissue without primary antibody. D. H&E section of FFPE tumor tissue.
E. Consecutive section of the same tumor treated with pressure cooker antigen retrieval and stained with the MS110 antibody showed that many
of the cells exhibit distinct nuclear staining (2). F. Consecutive control section of FFPE tissue without primary antibody. (×200).
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tion carrier for BRCA2 (6174delT), and patient no. 13
who was a mutation carrier for BRCA1 (185delAG).
No targeted mutations were found in the other 14
samples (1,2,3,5,6,7,10,11,12,14,15,20,21,and 22). Six
samples were not available (8,9,16,17,18, and 19).We
assayed BRCA1 immunohistology in our specimens,
including those from patients no. 4 and 13 before test-
ing their mutation status. In the frozen sections from
patient no. 4, there was moderate (3) BRCA1 nuclearFigure 4 BRCA1 protein in frozen and FFPE sections of poorly differe
(6174delT) mutation. A. H&E stained frozen section of the tumor. B. Cons
monoclonal AP16 antibody and the avidin-biotin peroxidase detection syst
nuclear staining (3); insert shows focal staining. C. Negative control section
from patient no.4. E. Consecutive section of the same tumor treated with p
showed that most of the cells exhibited strong nuclear staining (4), and ins
without primary antibody. (×200) insert (×2000).staining in the tumor cells, as well as in the surround-
ing lactating breast tissue (Figure 5). The contiguous
FFPE tissue from patient no. 4 expressed strong (4)
BRCA1 nuclear staining in the tumor and in the lactat-
ing ducts (Figures 4 and 5).
In contrast, we found diffuse, and irregular but distinct
(2) BRCA1 protein staining with the K-18 antibody, in
frozen tumor tissue from patient no. 13 with the BRCA1
mutation (Figure 6) The contiguous FFPE tissue stained
with the MS110 antibody was only very weakly stainedntiated adenocarcinoma (PDA) from patient no. 4 with a BRCA2
ecutive section of the same tumor stained with the mouse
em showed that many of the cells exhibited moderate punctate
using standard dilutions of mouse IgG. D. H&E section of FFPE tissue
ressure cooker antigen retrieval and stained with the MS110 antibody
ert shows strong staining. F. Consecutive control section of FFPE tissue
Figure 5 BRCA1 protein in frozen and FFPE sections from lactating tissue from patient no.4 with a BRCA2 mutation. A. H&E stained
frozen section of lactating tissue. B. Consecutive section of the same tissue stained with the mouse monoclonal AP16 antibody and the avidin-
biotin peroxidase detection system showed that many of the lactating cells showed punctate nuclear granules. C. Negative control section using
standard dilutions of mouse IgG. D. H&E section of FFPE lactating tissue. E. Consecutive section of the same tissue treated with pressure cooker
antigen retrieval and stained with the MS110 antibody showed that most of the lactating cells exhibited moderate homogeneous nuclear
staining (3). F. Consecutive control section of FFPE tissue without primary antibody. (×200).
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BRCA1 185delAG mutation in the contiguous paraffin
sample for patient no. 13, is compared to the normal se-
quence in patient no. 12. Neither of the tumors from pa-
tient no. 4 or from patient no. 13 showed loss of
heterozygosity (LOH) by homozygosity of the mutant al-
lele, as determined by PCR of the amplified fragments
(data not shown).Figure 6 BRCA1 protein in frozen and FFPE sections of poorly differe
mutation (185delAG). A. H&E stained frozen section of the tumor. B. Con
antibody and anti-rabbit IgG and avidin-biotin peroxidase detection system
shows diffuse staining. C. Consecutive section of the same tumor incubate
section of FFPE tissue from patient no.13. E. Consecutive section of the sam
with the MS110 antibody showed that many of the cells exhibited weak nu
control section of FFPE tissue without primary antibody. (×200) insert (×200After assessing BRCA1 protein staining by histopatho-
logical grade, we further grouped our BRCA1 protein
staining results by ER/PR status (Table 1). PDA samples
comprised eight out of ten specimens that were either
ER or PR negative, or were both ER/PR negative, al-
though the data are too few to permit statistical signifi-
cance. In addition, two of the ER/PR negative PDAs
were mutation carriers (Table 1). It is also interesting tontiated adenocarcinoma (PDA) from patient no.13 with a BRCA1
secutive section of the same tumor stained with rabbit polyclonal K-18
. Many of the cells exhibited diffuse nuclear staining (2), and insert
d with control rabbit IgG shows no appreciable staining. D. H&E
e tumor treated with pressure cooker antigen retrieval and stained
clear staining (1), and insert shows unstained nuclei. F. Consecutive
0).
Figure 7 BRCA1 protein localization in frozen and FFPE sections of poorly differentiated adenocarcinoma (PDA) from patient no. 22
using avidin-biotin-detection system. A. H&E stained frozen section of tumor. B. Consecutive section of the tumor stained with mouse
monoclonal AP16 antibody and biotinylated anti- mouse IgG showed that few of the cells showed distinct, punctate nuclear staining (2), and
insert shows focal staining. C. Standard dilution of mouse IgG served as negative control. D. H&E section of FFPE tissue from patient no.22. E.
Consecutive section of the same tumor treated with pressure cooker antigen retrieval and stained with the MS110 antibody showed that few of
the cells exhibited distinct nuclear staining (2) and insert shows darkly stained and unstained nuclei. F. Consecutive control section of FFPE tissue
without primary antibody. (×200) insert (×2000).
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BRCA1 staining are ER/PR positive.
We compared immunoperoxidase and immunofluor-
escence detection procedures to study BRCA1 protein
staining in the frozen and FFPE PDA tissue from patient
no. 22. With the AP16 antibody and immunoperoxidase
detection, many of the tumor cell nuclei showed punctate
granular staining of category (2) in the frozen sections
(Figure 7). Distinct nuclear staining (2) of many of the
tumor cells was found in the contiguous FFPE sections
with the MS110 antibody (Figure 7). We then compared
immunofluorescence staining with the K-18 antibody onFigure 8 DNA sequencing chromatogram illustrates the mutation, 18
nucleotides AG at position 185 (∇) in BRCA1 gene in sample no. 13 (l
shown in top panel. Arrows indicate the position of AG deletion. In both, D
determined using the primers flanking the mutation loci.the frozen sections from patient no. 22; BRCA1 protein
nuclear localization appeared similar, although there was
greater sensitivity with immunofluorescence (Figure 9A).
Between 1 and 5 punctate bodies (green) were visible in
tumor cell nuclei; the interstitial cell nuclei were only very
weakly stained or unstained, although there was intrinsic
fluorescence in the stromal tissue. In asynchronously
growing MCF7 cells, we found varying staining patterns
with the K-18 BRCA1 antibody (Figure 9B). The patterns
included strongly fluorescent nuclei, cells with intra-
nuclear punctate bodies, and cells with nuclear and cyto-
plasmic staining.5delAG, resulting from the deletion of two consecutive
ower panel). DNA sequences from sample no. 12 (wild type) are
NA from FFPE tissues were amplified and nucleotide sequences were
Figure 9 Immunofluorescence staining of BRCA1 protein
localization in poorly differentiated adenocarcinoma (PDA)
from patient no.22 and an asynchronous culture of MCF7 cells.
A. The tumor is stained with rabbit polyclonal K-18 antibody and
FITC-labelled goat anti-rabbit serum. Many tumor cell nuclei show
both 1–5 punctate bodies (green) and large round central structures
(green) and the interstitial cell nuclei are very weakly stained. B.
Asynchronous culture of MCF7 cells stained with rabbit polyclonal
K-18 antibody and FITC-labelled goat anti-rabbit. BRCA1 staining
consisting of fluorescent nuclei, intra-nuclear punctate bodies
(green) and cytoplasmic staining. (×300).
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asynchronously growing MCF7 cells (Figure 10) and
HCC1937 cells (Figure 11). The MCF7 cells exhibited
varying staining patterns with both antibodies; with the
BRCA1 antibody, the nuclear patterns included nuclei
with many small dot-like speckles, nuclei with punctate
bodies and speckles, and nuclei with round centrally
placed bodies (Figure 10A). On the same field, the mouse
monoclonal antibody to nucleolin stained nucleoli and
many dot-like nuclear speckles (Figure 10B). The co-
localization of BRCA1 protein and nucleolin occurred fre-
quently in nucleoli (which are phase dense in Figure 10D)
and in some nuclear speckles (Figure 10C). In HCC1937
cells, co-localization of BRCA1 antibody (K-18) and
nucleolin 7G2 was found in nuclear speckles, nucleoli,
and portions of nucleoli, however, some of the nucleoli,
exhibited patches of BRCA1 (green), nucleolin (red), and
merged (yellow) regions (Figure 11).We performed Western blotting to confirm BRCA1
protein levels in MCF7 and HCC1937 cells (Figure 12).
Relatively low levels of a 210 kDa BRCA1 species were
found in the HCC1937 extracts (5382insC product),
compared to the higher levels in control MCF7 extracts
(wild-type BRCA1).
Discussion
We found concordant BRCA1 protein staining in frozen
and FFPE tissue specimens of 22 randomly selected
breast tumors. Using anti-BRCA1 antibodies AP16 and
K-18 on frozen sections we found punctate BRCA1
staining and more homogeneous staining with the
MS110 antibody in variable numbers of tumor cell nu-
clei and nucleoli of breast cancer patients [26,27]. There
was variable homogeneous nuclear staining with the
MS110 antibody in contiguous pressure cooker antigen-
retrieved FFPE tumor tissue. These results extend our
previous studies which showed BRCA1 nuclear and nucle-
olar localization in frozen tissue sections and estradiol-
treated MCF7 cells [26-28]. However, Bogdani et al. [29]
using D-20, K-18, I-20, and C-20 anti-BRCA1 antibodies
on Bouin’s fixed tumor tissue of young and old patients
with breast cancer, found nuclear and cytoplasmic BRCA1
staining in about 50% of sporadic specimens, and less
staining in tumor cells in young patients and one with a
germline mutation. Perez-Valles et al. [30] showed pre-
dominantly cytoplasmic staining with the D-20, I-20, and
K-18 polyclonal antibodies in FFPE samples of both tu-
moral and non-tumoral cells, but nuclear and cytoplasmic
staining with the I-20 antibody in FFPE samples after
microwave pre-treatment in breast tumor tissue. Recently,
Milner et al. [31] in an extensive evaluation of MS110
antibody staining as a patient selection biomarker found
sub-cellular localization to the nucleus. However, they
concluded that although MS110 did detect BRCA1 in
FFPE tumor tissue samples, BRCA1 expression levels in
standard methodologies were not reproducible enough to
enable its use as a selection marker.
We found less BRCA1 nuclear staining in the tumor
tissue of frozen tissue specimens and in contiguous
FFPE tissue with higher histological grade. The inverse
correlation between lower BRCA1 protein expression
and higher histological grade has been well established
[24]; less nuclear staining has also been described in es-
trogen receptor/progesterone receptor/HER2-negative
(triple negative) breast tumor tissue [32-34].
In a patient with a BRCA1 mutation (185delAG), we
found FFPE tumor tissue stained with the MS110 anti-
body was mostly negative and the BRCA1 staining in the
FFPE normal tissue was weakly positive. These results
are consistent with reports showing that heterozygous
germline BRCA1 mutations involved in familial breast
cancer produce truncated protein, preferential LOH of
Figure 10 Co-localization of BRCA1 antibody (K-18) and nucleolin (7G2) in MCF7 cells. A. Rabbit polyclonal BRCA1 antibody stains many
cell nuclei (green). The varied nuclear patterns include many small dot-like speckles, punctate bodies and speckles, and round centrally placed
bodies. B. Mouse monoclonal antibody to nucleolin stains nucleoli and many dot-like speckles (red). C. Nuclei which stain for BRCA1 (green)
merge with nucleolin (red) to show co-localization(yellow). The merge occurs both in nucleoli (which are phase dense in D) and in some nuclear
speckles. Not all of the nucleoli show co-localization. D. Nomarski image of the same field as A,B,C. Bar = 20 μm.
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reactivity [35-37]. However, Perez-Valles et al. [29] did
not find differences in nuclear BRCA1 protein expres-
sion between cases with and without BRCA1 germline
mutations by immunohistochemistry.
In our study, we also found diffuse, and irregular
BRCA1 protein staining with the K-18 antibody in the
frozen section tumor tissue from a patient, with a
BRCA1 mutation (185delAG), which is difficult to ex-
plain. Although there is no direct evidence that the
BRCA1 185delAG mutation results in transcription of a
functional truncated protein, Buisson et al. [38] have
reported that mRNAs from patients with the BRCA1
185delAG mutations are able to elude the non-sense
mediated mRNA decay (NMD) pathway and remain
stable in the cell. O’Donnell et al. [39] proposed that
the truncated protein product may modulate chemo-
sensitivity. Wilson et al. [24] suggest that the 185delAG
mutation results in deletion of most of the protein, includ-
ing the MS110 epitope which maps between aa residues
89–222. However, the 185delAG BRCA1 N-terminus 39
aa may have an epitope within aa 70–89 that is detected
by the K-18 antibody.We have found positive BRCA1 protein nuclear stain-
ing in frozen and FFPE tumor and lactating tissue from
a patient with a BRCA2 mutation. However, as our sam-
ples were tested for all three targeted mutations, there is
no evidence that BRCA1 is altered in this patient. There-
fore these results are consistent with evidence that al-
though BRCA1 protein is a negative regulator of cell
growth, BRCA1 expression is up-regulated, during cell
proliferation and lactation [40-42].
In our FFPE sections we frequently found that normal
epithelial tissue surrounding the tumor had strong nu-
clear staining with the MS110 antibody, although weak
staining was observed in the normal tissue in two of our
specimens. This generally agrees with data that normal
tissue surrounding the tumor has positive nuclear stain-
ing with the MS110 antibody [22]. However, it has also
been observed by Bogdani et al. [29] using the I-20 poly-
clonal antibody that positive nuclear staining was found
in 75% of normal tissue from both young and old pa-
tients, and that nuclear staining was absent in the nor-
mal tissue of six samples. Milner et al. [31] also found
that associated non-neoplastic normal breast epithelium
showed moderate to strong nuclear staining with no
Figure 11 Co-localization of BRCA1 antibody (K-18) and nucleolin (7G2) in HCC1937 cells. A. rabbit polyclonal BRCA1 antibody stains many
cell nuclei (green). The varied nuclear patterns include dot-like speckles, and intra-nuclear granules. B. Mouse monoclonal antibody to nucleolin
stains nucleoli and many dot-like speckles (red). C. Some nuclear speckles, nucleoli, and portions of nucleoli stain for BRCA1(green) and nucleolin
(red) to show co-localization (yellow). The arrow points to a nucleolus, in which there are BRCA1 (green), nucleolin (red), and merged (yellow)













Figure 12 BRCA1 protein levels in MCF7 and HCC1937 cells.
Extracts of HCC1937 and MCF7 cells were normalized for protein
content, separated by 5% SDS PAGE, and immunoblotted
for BRCA1 with mAb MS110. HCC1937 extracts revealed low
levels of a 210 kDa BRCA1 species, when we compared
100 μg of total protein in the HCC1937 extracts (5382insC product)
with 50 μg, 100 μg, and 150 μg of control MCF7 extracts
(wild-type BRCA1).
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epithelium.
In summary, our immunohistological studies of frozen
and FFPE tissues of breast tumors with monoclonal anti-
bodies MS110 and AP16 and the polyclonal antibody K-18,
with immunoperoxidase and immunofluorescence detec-
tion, have shown that BRCA1 protein has a nuclear and
nucleolar localization. We have used freezing in liquid N2,
followed by -20o C methanol fixation of the captured fro-
zen sections in order to minimize translocation of antigen
during fixation. Guerra–Rebollo et al. [43] also found that
after using methanol fixation, BRCA1 was localized in nu-
cleoli, but after ᵧ-irradiation BRCA1 was depleted from the
nucleolus, and associated with ionizing-radiation induced
foci (IRIF).
We have previously shown co-localization of BRCA1
protein and nucleolin in the nucleolus and speckles of
MCF7 and HeLa cell nuclei [26,27]. In the present
study, we found that in the mutant HCC1937 cell line
(5382insC), co-localization of BRCA1 protein and
nucleolin occurred in aberrant, patched regions in
some nucleoli. HCC1937 extracts revealed low levels
of a 210 kDa BRCA1 species consistent with the
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BRCA1 C terminus [44]. This result suggests that pro-
tein truncation at the C-terminus may yield variable
nucleolar localization. The functions of BRCA1 protein
are yet to be fully elucidated, however, BRCA1 protein
participates in many signaling pathways involved in
transcription, checkpoint control, and is recruited for
the formation of DNA repair complexes in association
with proteins such as Mre11-Nbs1-Rad50, and BRCA2
[45]. The data that BRCA1 is localized in the nucle-
olus, in addition to speckles, may explain a possible
functional participation in processes of ribosomal bio-
synthesis, cell cycle progression, and as a reservoir for
complexes formed in response to cellular stress and
DNA repair [27,43].
The function of BRCA1 protein in tumorigenesis has
been found to be complex, and as a tumor suppressor, it
is postulated that reduced expression leads to multiple
abnormalities, including a defect in the homologous re-
combination (HR) pathway of DNA repair. These defects
are associated with a hypersensitivity to many agents
that cause DNA double strand breaks, such as ionizing
radiation (IR). In a study testing breast cancer biopsies
irradiated ex vivo for the ability to form BRCA1,
FANCD2 and RAD 51 foci, Willers et al. [46] detected
BRCA1 DNA repair foci defects in triple-negative breast
cancers, a phenotype associated with BRCA1 deficiency.
In addition, Burga et al. [47] found an association of in-
creased proliferation and increased BRCA1 immunohis-
tochemical expression in breast cancer epithelial cells
from BRCA1 mutation carriers, which they ascribed to
epidermal growth receptor pathway activation.
The data presented here support a role for BRCA1 in
the pathogenesis of sporadic and inherited breast can-
cers. The use of well-characterized reagents and possibil-
ities for co-localization experiments in both cell culture,
and frozen and FFPE tissues, may lead to further insights
into the molecular pathways involved in BRCA1 protein
function and possibly the further development of
targeted therapeutics.
Conclusions
We compared BRCA1 protein localization in frozen and
FFPE tissue, from 22 randomly selected patients with
breast carcinomas. We tested 16 of the tumor specimens
to determine whether they contained the common Ash-
kenazi Jewish founder mutations in BRCA1 (185delAG,
5382insC), and BRCA2 (6174delT). Two mutation car-
riers were identified: patient no. 4 who was a mutation
carrier for BRCA2 (6174delT), and patient no. 13 who
was a mutation carrier for BRCA1 (185delAG), and were
confirmed by gene sequencing.
In the frozen sections, the BRCA1 antibody staining
showed punctate, intra-nuclear granules in varyingnumbers of tumor, lactating, and normal cells In the
FFPE tissue, we found reduced BRCA1 nuclear staining
in breast tumor tissue compared to normal tissue, and
less BRCA1 staining with higher histological grade in
the tumors. The differences in staining between frozen
and FFPE sections based on a varied group of infiltrating
breast tumors, suggest that the sub-nuclear localization
of BRCA1 is best studied by comparison of frozen and
FFPE sections, using an array of BRCA1 antibodies, and
fixation procedures.
We have previously shown co-localization of BRCA1
and nucleolin, and cell cycle dependent BRCA1 nucle-
olar localization in MCF7 cells. In the present study, we
compared co-localization of BRCA1 and nucleolin in
MCF7 cells (wild type), and a mutant BRCA1 cell line,
HCC1937 (5382insC) and found altered sub-nuclear and
nucleolar localization patterns consistent with a func-
tional impact of the mutation on protein localization.
Materials and methods
This study was approved by the Institutional Review
Board of the Mount Sinai School of Medicine. We ran-
domly selected specimens of breast cancer tissue from
22 patients, not screened for ethnicity, which were sub-
mitted to the surgical pathology division of the Depart-
ment of Pathology between 1996 and 2000 and snap
froze them in liquid N2. The remainder of the tissue was
routinely fixed in formalin and paraffin embedded. Fam-
ily history, histopathological diagnosis, age of onset,
lymph node status, and estrogen, progesterone receptor
(ER, PR) status were recorded for each patient and en-
tered into a database. The series of infiltrating breast
carcinomas was classified as: ductal, lobular, medullary,
colloid, or tubular; and if ductal, was graded moderately
differentiated adenocarcinoma (MDA) or poorly differ-
entiated adenocarcinoma (PDA) according to modified
Bloom-Scarff-Richardson criteria [48]. Once the clinical
data was collected, each patient and corresponding
specimen was assigned a number; and our statistician,
acting as a third-party liaison assumed responsibility
for maintaining the database. DNA results were com-
municated to the statistician, who then entered the
anonymized information into the database.
Primary antibodies
Mouse monoclonal BRCA1 antibodies: MS110 r 1–304;
MS 13 r 1–304; AP 16 r 1,313–1863; and SG 11 r-1846–
1863 (22, Oncogene Research Products, CA); and the
K-18 rabbit antibody, r-70–89 [49], Santa Cruz Tech-
nology, CA), were prepared at 1:20 dilution. For
antigen-retrieved FFPE tissue the MS110 antibody was
diluted 1:200. The specificity of the K-18 antibody
binding was checked by pre-absorption with the pep-
tide [26], Santa Cruz Technology, CA] and stained in
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mAb 7G2, a mouse monoclonal antibody was used at
1:2 [50], kind gift from S. Pinol-Roma].
Immunohistology
The methodology for preparing the frozen sections has
been described previously [26]. Briefly, tissue snap frozen
in liquid N2 is mounted at about −8°C in oil (an approxi-
mately eutectic mixture of aliphatic esters with a freezing
point of about −9°C), frozen at about −25°C, and sectioned
using a special adhesive tape to capture the section. The
section is transferred to a −13°C microscope slide coated
with a UV-polymerizable adhesive and treated with a flash
of UV to polymerize the adhesive and adhere the section
(Leica). The slide-mounted, 6-micron frozen sections were
melted at room temperature and air dried for 1 hour be-
fore being dipped for 30 to 60 sec. in −20°C methanol, and
then dried for 5 minutes before being used. Before stain-
ing, sections were re-hydrated in PBS, and then incubated
in primary rabbit or mouse antibodies. Normal goat serum
was used to block nonspecific immunoglobulin binding
and the sections were incubated in a humidified atmos-
phere at 4°C for 16 hours. Standard dilutions of normal
rabbit or mouse IgG served as negative controls for each
experiment. For immuno-peroxidase staining, the avidin-
biotin-peroxidase complex technique (Dako Corp., CA)
was used. For immunofluorescence, the slides were incu-
bated with species-specific, FITC or TXR-conjugated sec-
ondary antibodies for 30 min, at a 1:100 dilution, washed
extensively in PBS, and mounted with Vectashield with or
without DAPI (4,6-diamidino-2-phenylindole) (Vector
Labs., CA). Fluorescently stained cells or tissues were ob-
served using a Zeiss axiophot microscope equipped with a
40X Plan-Neofluar objective, and a Leica TCS-SP (UV)
confocal laser scanning microscope.
Paraffin sections were deparaffinized by heating at 60o
C for 30 min followed by two 5-min immersions in xy-
lene. The tissue sections were rehydrated through a
graded series of alcohols, followed by two 15 min rinses
in distilled water. They were heated in a pressure cooker
for four min in 0.05 M citrate buffer (pH 5.6). There-
after, the slides were washed twice for 15 min each in
phosphate buffered saline (PBS) (Sigma). The BRCA1
monoclonal antibody MS110 produced staining of
tumor cell nuclei at a 1:200 dilution. The UltraVision
LP (ThermoScientific) detection system was used for
diaminobenzidine (DAB) staining. Immunoreactivity was
qualitatively assessed by the proportion of reactive cells
and the intensity of staining: weak, faint (1), distinct (2),
moderate (3), and strong (4).
Cell culture
For the cell studies, MCF7 and HCC1937 [51] were
grown in RPMI 1640 supplemented with 10% heat-inactivated FCS, 50 U/ml penicillin, and 50 μg/ml
streptomycin. The cells were grown on chamber slides,
washed three times in PBS, immersed in liquid N2 for
13 seconds, and then followed by 20 minute fixation in
−20°C methanol. After a wash in PBS, the slides were in-
cubated in primary rabbit or mouse antibody, or co-
localized with both antibodies simultaneously. After
subsequent PBS rinses, the slides were incubated with
species-specific, FITC or TXR-conjugated secondary
antibodies for 30 minutes, at a 1:100 dilution, washed
extensively in PBS, and mounted with Vectashield with
or without DAPI (Vector Labs., CA). Fluorescently
stained cells were observed using a Zeiss axiophot
microscope equipped with a 40x Plan-Neofluar object-
ive, and a Leica TCS-SP (UV) confocal laser scanning
microscope.
Western blotting
For biochemical analysis, MCF7 and HCC1937 cells were
grown on 100 mm culture dishes. Subconfluent, asyn-
chronously dividing cells were rinsed once with 5 ml ice
cold PBS and lysed in 1% CHAPS lysis buffer (150 mM
NaCl, 10 mM HEPES, pH7.4, 1% CHAPS 3- [(3-
Cholamidopropyl-dimethylammonio-1-propanesulfonate)]
supplemented with protease and phosphatase inhibitors.
For the detection of BRCA1, 100 μg whole cell lysate
(WCL) from HCC1937 was compared to 50, 100, and
150 μg WCL from MCF7 cells and resolved using 6%
SDS-PAGE. Proteins were then transferred to PVDF
membrane, blocked for 1 h with 5% nonfat milk in TBS-T
(20 mM Tris-CL, pH 8.0, 150 mM NaCl, 0.05% Tween
20) at room temperature, incubated with the primary anti-
body MS110 (AB-1) 1:500 in blocking solution overnight
at 4°C, the membrane was washed three times in TBS-T,
the membrane was then incubated with goat anti-mouse
(HRP) secondary antibody 1: 4000 for 45 min at room
temperature, washed three times 10 minutes, and proteins
were detected using chemiluminescence HRP detection
(Millipore).
Genotyping
DNA from 16 anonymous breast cancer specimens was
extracted from frozen tissue. A multiplex (triplex) poly-
merase chain reaction was performed to amplify frag-
ments for the common Jewish Ashkenazi mutations in
BRCA1 (185delAG, 5382insC), and BRCA2 (6174delT).
The products were hybridized with normal and mutant
probes for each of three mutations as previously de-
scribed [12]. In accordance with IRB regulations, the
anonymized DNA from the two mutation carriers was
sent to Myriad Genetics (Salt Lake City, Utah) for gene
sequencing. To confirm the BRCA1 185delAG mutation,
DNA from FFPE slides of specimen no.13 was isolated
using the BiOstic FFPE tissue DNA isolation kit (Mo Bio
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nucleotide primers flanking the mutation loci: BRCA1,
185delAG forward (5′-GGATTTATCTGCTCTTCGCG
TT-3′) and 185delAG reverse (5′-TGTCTTTTCTTC
CCTAGTATGT-3′). The PCR product was purified and
subjected to DNA sequencing with the primers used for
the amplification. As a negative control, DNA from spe-
cimen no.12 was amplified and sequenced using the
same primers. The sequences were compared with the
reference sequences using program BLAST.
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